The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene ...

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...

Enrollment and randomization in ZUPREME-1 was completed in three months. In March 2025, Zealand Pharma and Roche entered a collaboration and license agreement to co-develop and co-commercialize ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.